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CASE PRESENTATION
A 20-year-old woman was referred to Peking University
First Hospital, Beijing, China, owing to massive pulmonary
hemorrhage and gross hematuria. She had been well until
2 years before admission when she was diagnosed with
Graves’ disease and was treated with propylthiouracil
(PTU) 300 mg/day first and then maintained with PTU
100 mg/day. Five months before admission, she
complained of palpitations and was found to have an
elevated serum T3 and T4 and decreased thyroid
stimulating hormones. In response, the dose of PTU was
changed to 300 mg/day by her local doctors. Shortly
thereafter, she started to complain of arthralgia, myalgia,
and skin rash. Three months before admission, she
developed a cough, hemoptysis, and gross hematuria, and
subsequently a gradual decline in her hearing, ‘red eye’,
and weight loss. One week before admission, her PTU dose
was further increased to 450 mg/day and then the patient
became severely ill with massive pulmonary hemorrhage.
At physical examination on admission, her paleness,
exophthalmos, and goiter were revealed. The blood
pressure was 120/80 mm Hg, the pulse 96 beats/min, the
respiratory rate 24 breaths/min, and the temperature
37.21C. The body weight was 45 kg. Auscultation of the
lungs revealed scattered expiratory wheezes and coarse
bronchial breath sounds. A cardiac examination revealed
tachycardia with normal heart sounds and no murmurs,
rubs, or gallops. The abdomen was soft, nontender. There
was no edema on lower extremities.
Laboratory data are shown in Tables 1 and 2. Chest
radiography indicated massive pulmonary hemorrhage
(Figure 1a). Her serum perinuclear cytoplasmic stained
pattern on ethanol-fixed neutrophil was positive with
specificity to myeloperoxidase, lactoferrin, and azurocidin.
Anti-nuclear antibody and anti-glomerular basement
membrane antibody were negative.
DIAGNOSIS
1. PTU-induced anti-neutrophil cytoplasmic antibody
(ANCA)-associated systemic vasculitis.
2. Hyperthyroidism (Graves’ disease).
CLINICAL FOLLOW-UP
After admission, the PTU was withdrawn immediately. She
was treated with plasmapheresis twice (2000 ml fresh plasma
each time) and methylprednisolone pulse therapy (500 mg on
the other day for three times). She improved dramatically,
her hemoptysis ceased, and chest radiography became clear
just 4 days after admission (Figure 1b). Percutaneous renal
biopsies demonstrated necrotizing crescentic glomerulo-
nephritis (Figure 2). Then she received oral prednisone
1 mg/kg/day combined intravenous pulse cyclophosphamide
0.8 g/m. She achieved complete recovery within weeks and
she has been followed up for 3 years.
DISCUSSION
The patient presented herein was diagnosed with Graves’
disease 2 years before admission and was treated with PTU.
Five months before admission, she clearly had a relapse of
hyperthyroidism and was administrated with PTU at 300 mg/
day, then she gradually developed a multi-system disease like
systemic vasculitis. However, her local doctors failed to
recognize it as a severe side effect of PTU, and in fact even
increased the dosage of PTU to 450 mg/day, and eventually
she experienced a life-threatening diffuse pulmonary hemo-
rrhage and necrotizing crescentic glomerulonephritis. After
successful intensive immunosuppressive therapy, she
achieved complete recovery within weeks. Her corticosteroid
and cyclophosphamide were stopped 6 months after initia-
tion of therapy. However, her serum perinuclear cytoplasmic
stained pattern on ethanol-fixed neutrophil and anti-
myeloperoxidase (MPO) antibodies remained persistently
positive with a low titer, although there has been no flare of
clinical vasculitis during our 3-year follow-up. Despite our
suggestion that she could take methimazole (MMI) as a
substitute of PTU to control hyperthyroidism, she insisted to
undergo subthyroidectomy.
ANCA-associated systemic vasculitis (AASV) is a group of
autoimmune diseases including Wegener’s granulomatosis,
microscopic polyangiitis, and Churg–Strauss syndrome.1
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There is a high specificity of c-ANCA/proteinase 3-ANCA for
Wegener’s granulomatosis and p-ANCA/MPO-ANCA for
microscopic polyangiitis. ANCA was more than a serological
marker of disease and could stimulate leukocyte to undergo a
respiratory burst and degranulate granular constitutes in a
wide variety of ways, resulting in the release of reactive
oxygen species, granule proteases, cytokines, chemokines,
and adhesion molecules. Leukocytes activated by ANCA
could also adhere to endothelium and cause endothelial cell
damage.2,3 Recent development in the field of vasculitis is the
increasing recognition that PTU could induce AASV.
Hyperthyroidism is a common endocrine disease and
medication is the preferred choice of treatment, especially in
oriental countries such as China and Japan. PTU and MMI
are the most commonly used antithyroid agents in China.
Recently, several cross-sectional and prospective studies have
demonstrated that PTU could induce AASV.4–8 Our recent
cross-sectional study screened serum ANCA, using indirect
Table 1 | Laboratory data
Variable Value Normal range
Hemoglobin (g/dl) 7.8 11–15
White cell count ( 103/mm3) 8.8 4.0–10.0
Platelet count ( 103/mm3) 393 100–300
Erythrocyte sedimentation rate (mm/h) 120 o20
Urinary protein 1.86 o0.15
Urinary RBC (/HP) 80–100
Creatinine clearance (ml/min) 84.84 80–120
Alb (g/l) 30.3 35–55
IgG (g/l), 10.2 7.23–16.85
IgA (g/l) 1.43 0.69–3.82
IgM (g/l), 1.92 0.63–2.77
C3 (g/l) 0.48 0.85–1.93
CRP (+) ()
PaO2 (mm Hg) 73 95–100
T3 (nmol/l) 1.70 1.7–2.3
T4 (nmol/l) 135.22 65–155
TSH (IU/ml) 0.05 0.35–0.55
Anti-TG antibody () ()
Anti-TPO antibody () ()
Anti-TSH receptor antibody () ()
CRP, C-reactive protein; HP, hyperpower field; Ig, immunoglobulin; RBC, red blood
cells; TG, thyroglobulin; TPO, thyroid peroxidase; TSH, thyroid stimulating hormones.
Table 2 | Prevalence of serum ANCA in patients with
hyperthyroidism receiving various treatment modalities
Groups Cases (n) IIF-ANCA positive
Untreated 34 1 (2.9%)
Treated with PTU 62 14 (22.6%)*
Treated with MMI 77 0
Treated with PTU and MMI 43 7 (16.3%)
Total 216 22 (10.2%)
*o0.05.
ANCA, antineutrophil cytoplasmic antibodies; MMI, methimazole; PTU, propylthiour-
acil.
Figure 1 | Chest radiography. (a) Four days before admission, bilateral pulmonary diffuse exudative lesions; (b) 4 days after treatment, both
lungs were clear.
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immunofluorescence assay, in 216 out-patients with hyper-
thyroidism in Peking University First Hospital. The patients
were divided into four subgroups: untreated, treated with
PTU only, treated with MMI only, and treated with both PTU
and MMI. It was revealed that PTU, not MMI, was associated
with the production of ANCA in patients with hyper-
thyroidism, and ANCA was less likely caused by underlying
thyroid disease.8 However, it has been found that majority of
patients with positive serum ANCA did not have clinical
evidence of vasculitis.8
The etiology of primary AASV is unknown and the
mechanism of ANCA production was not clear. Further study
on PTU-induced ANCA and vasculitis might provide useful
information.
The prevalence and antigen specificity of PTU-induced ANCA
PTU-induced ANCA-associated vasculitis was first reported
by Dolman et al.9 The reported prevalence of anti-thyroid
drug-induced ANCA ranged from 4 to 46%.10 Our cross-
sectional study revealed that 22.6% of patients treated with
PTU had positive serum ANCA,8 suggesting that PTU-
induced ANCA is common.
In the literature, it has been suggested that PTU-induced
ANCA usually recognized multiple antigens.10 In our cross-
sectional study, seven highly purified known ANCA antigens,
including MPO, proteinase 3, human leukocyte elastase,
bactericidal/permeability-increasing protein, cathepsin G,
lactoferrin, and azurocidin, were used as solid-phase ligands
in enzyme-linked immuno sorbent assay to determine ANCA
specificities. Most sera could recognize more than one
antigen, and lactoferrin and human leukocyte elastase are
the two most common target antigens. Therefore, it was
concluded that PTU-induced ANCA were B-cell polyclonal
activation.8
The difference between PTU-induced ANCA and ANCA of
patients with primary AASV
Compared with those with primary AASV, patients with
PTU-induced ANCA-positive vasculitis were younger and
mostly female, and this might merely be a reflection of the
greater prevalence of thyroid disease in young female
subjects. In primary AASV, substantial evidence has suggested
that the level of anti-MPO and anti-proteinase 3 antibodies,
their epitope recognition, antibody subclasses, and antibody
avidity might be associated with clinical expression of
disease. We have speculated that studies on immunological
characteristics of PTU-induced ANCA might provide useful
information on the pathogenetic role of ANCA in primary
vasculitis.
ANCA in patients with primary AASV usually recognized
only one antigen, either MPO or proteinase 3;1 however,
PTU-induced ANCA usually recognize multiple antigens.8
Comparing with anti-MPO antibodies in sera from patients
with primary AASV, PTU-induced anti-MPO antibodies
might recognize restricted epitope(s).11 A further study of
ours indicated that PTU-induced anti-MPO antibodies
usually had higher titer but lower avidity.12 Anti-MPO
immunoglobulin (Ig)G3 subclass was not detectable in sera
from patients with PTU-induced ANCA.13 It has been known
that IgG3 exhibits a strong complement-activation capacity
and binds firmly to Fc receptors on mononuclear cells.
Therefore, it was speculated that anti-MPO antibodies from
patients with PTU-induced ANCA might be less pathogenic,
and PTU-induced anti-MPO antibodies could keep positive
for years in remission. However, the high titer of anti-MPO
IgG4 subclass in active phase decreased much quicker than
that in primary AASV.13 It was believed that IgG4 production
was more likely driven by chronic antigen stimulation.
Therefore, we speculated that PTU-induced anti-MPO
antibodies might be driven by repeated PTU administration,
and the titer of anti-MPO antibodies declined quickly after
withdrawal of PTU. These studies suggested that the
mechanisms of ANCA production might be different between
patients with PTU-induced vasculitis and patients with
primary AASV.
The risk factors for patients with PTU-induced ANCA to
develop clinical vasculitis
Several studies, including ours, have demonstrated that
majority of patients with PTU-induced ANCA did not have
clinical evident vasculitis.8,10 In our series, only 28.6% (4/14)
Figure 2 | Light microscopic examination of percutaneous renal
biopsy: necrotizing glomerulonephritis.
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of patients with PTU-induced ANCA had clinical vasculitis.8
These phenomena provide us a unique opportunity to
investigate the risk factors to develop vasculitis by comparing
the immunologic characteristics of ANCA from patients with
PTU-induced AASV and patients with PTU-induced ANCA
but without clinical vasculitis.
In previous reports, MPO-ANCA was predominant in
patients with PTU-induced AASV, furthermore, it was
suggested that patients with MPO-ANCA might be at
increasing risk of developing overt clinical vasculitis. Our
recent study indicated that the prevalence of MPO-ANCA in
patients with vasculitis was significantly higher than that in
patients without vasculitis (Table 3), which provided further
evidence to support the notion that the occurrence of MPO-
ANCA might be associated with the development of clinical
vasculitis. Our further studies also suggested that patients
with PTU-induced AASV tended to have higher titer and
higher avidity of anti-MPO antibodies than those without
clinical vasculitis.12,13
In vasculitides, it was suggested that endothelium was not
only the target of damage but also an active participant of
vasculitic injury.14 Anti-endothelial cell antibodies have been
described in various autoimmune and vasculitic disorders.15
They have been implicated in the pathogenesis of vascular
injury common to these disorders. One of our studies found
that majority (10/11) of patients with active PTU-induced
AASV had serum anti-endothelial cell antibodies and they
disappeared in remission quickly, however, patients with
PTU-induced ANCA but without clinical vasculitis did not
have anti-endothelial cell antibodies.16 This study provided
direct evidence that anti-endothelial cell antibodies might be
involved in the pathogenesis of AASV.
The pathogenic mechanism of PTU-induced ANCA (follow-up)
The pathogenesis of PTU-induced AASV is still not yet clear.
Evidences suggested that the interaction between PTU and
the target ANCA antigen might attribute to the pathogenesis
of PTU-induced vasculitis. Lee et al.17 demonstrated that the
structure of MPO could partially changed by the repeated
administration of PTU, and Jiang et al.18 suggested that PTU
could serve as an MPO substrate and the metabolites might
induce autoimmunity by exposing autoreactive lymphocytes
to abnormal forms of self-material.
Our current laboratory investigation suggested that PTU
could completely inhibit the enzyme actitivity of MPO in
vitro, and that IgG fraction, purified by Protein G affinity
chromatography from patients with PTU-induced ANCA,
could partially inhibit the enzyme activity of MPO (un-
published data). Further studies are needed to clarify the
interaction between PTU, MPO, and anti-MPO antibodies.
The association between cumulative dosage of PTU or
duration of PTU treatment and the development of PTU-
induced ANCA was not clear. Why some patients treated with
PTU were susceptible to develop serum ANCA was also not
known either. It was speculated that genetic background
might be a contributing factor, but this needs to be further
investigated.
The management of PTU-induced ANCA-associated vasculitis
The nonspecific symptoms such as fever, malaise, and
arthralgia could resolve quickly after cessation of PTU, which
suggested that PTU was closely related to the appearance of
symptoms. In two patients in our series who failed to
withdraw PTU in time, the renal function deteriorated
rapidly and they progressed to end-stage renal disease
eventually,19 which also suggested that continued adminis-
tration of PTU in PTU-induced AASV might be associated
with a poor prognosis. Therefore, it is reasonable to
recommend that PTU should be discontinued in patients
with PTU-induced AASV.
Some patients did not need further anti-thyroid treatment
because of euthyroid state when they were tested ANCA
positive. The thyroid function of some patients resolved
during administration of prednisone, which suggested that
prednisone might suppress the autoimmune activity of
Graves’ disease.7 Although MMI had structural similarities
with PTU, our previous study8 had clearly demonstrated that
MMI was not associated with the occurrence of ANCA and
vasculitis. Therefore, we recommended that MMI might be
considered as a substitution of PTU if necessary. Of course,
other treatment modalities could also be considered, such as
subthyroidectomy.
It was suggested that patients with PTU-induced vasculitis
with severe organ involvement should receive corticosteroid
and immunosuppressive agents according to the severity of
the illness. Patients with necrotizing crescentic glomerulo-
nephritis, like our presented case, should be treated with
methylprednisolone pulse therapy.20 However, the duration
of immunosuppressive therapy, especially maintenance
therapy, for patients with PTU-induced vasculitis was not
conclusive yet. We have treated 25 patients with PTU-
induced AASV and they were further followed up for 1–5
years (unpublished data); majority of the patients treated
with immunosuppressive therapy discontinued corticosteroid
and immunosuppressive agents within 12 months success-
fully and no relapse was observed during subsequent follow-up.
Table 3 | Comparison of immunologic parameters between
patients with PTU-induced AASV and patients with






Prevalence of anti-MPO Ab 50% 94.1% 0.002
Titer of anti-MPO Ab (lgT)a 2.5470.66 3.6270.29 o0.001
Affinity of anti-MPO Ab (aK, mol/l)b 0.14 107 4.47 107 o0.001
Positive AECA 0/10 10/11
AASV, ANCA-associated systemic vasculitis; Ab, Antibody; AECA, Anti-endothelial
cell antibodies; ANCA, anti-neutrophil cytoplasmic antibodies; Ig, immunoglobulin;
MMI, methimazole; MPO, myeloperoxidase; PTU, propylthiouracil.
aThe titer of anti-MPO antibodies was expressed as a logarithmic value.
bThe functional affinity constant (aK) was expressed as the reciprocal value of the
molar concentration of MPO in the liquid phase resulting in 50% inhibition of
antibody binding.
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The current presented case was successfully treated with only
induction therapy of immunosuppression for 6 months and
without maintenance therapy. Our experience suggested that
the duration of immunosuppressive therapy in patients with
PTU-induced vasculitis could be much shorter than that in
patients with primary AASV as long as PTU was withdrawn,
although some patients had their serum ANCA positive for
years.
SUMMARY
PTU-induced ANCA is not rare and some patients will have
overt clinical vasculitis. The immunologic characteristics of
PTU-induced ANCA and management of patients with PTU-
induced AASV might be different compared with that of
patients with primary AASV.
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